### Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Form 4	M PHARMACEU 2015	TICALS,	INC								
March 09, 2015 <b>FORM 4</b> Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses)						N OMB Number: Expires: Estimated burden hou response	Sumber:3235-028Number:January 31Expires:200Estimated averageburden hours perresponse0.				
1. Name and Address of Reporting Person <u>*</u> Slawin Kevin M.			2. Issuer Name <b>and</b> Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM] 3. Date of Earliest Transaction			g	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify				
				Day/Year)	ransaction			below)	below) Technology Off		
(Street) HOUSTON, TX 77030			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securi	ties Ac	quired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, -	(A) or of (D) 4 and 5) (A) or	)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Ro	eport on a separate lind	e for each cl	ass of sec	urities benef	Perso inforr requi	ns when nation red to r	o resp conta respo	indirectly. bond to the colle ined in this form nd unless the fo tly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 D S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 24.48	03/06/2015		А	60,000	(1)	03/05/2025	Common Stock	60,000	

#### Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address			Relationships		
<b>F B</b>	Director	10% Owner	Officer	Other	
Slawin Kevin M. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030	Х		Chief Technology Officer		
Signatures					

\*\*Signature of Reporting Person

/s/ Alan Musso, 03/06/2015 Attorney-in-Fact

Date

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

25% of the shares subject to the stock option vest and become exercisable on March 6, 2016, and the remaining shares subject to the stock (1) option vest and become exercisable in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.